

Cancer Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/C95BB2D66C86EN.html>

Date: May 2024

Pages: 134

Price: US\$ 6,499.00 (Single User License)

ID: C95BB2D66C86EN

Abstracts

The 7 major cancer pain markets reached a value of US\$ 1,717.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 2,523.4 Million by 2034, exhibiting a growth rate (CAGR) of 3.56% during 2024-2034.

The cancer pain market has been comprehensively analyzed in IMARC's new report titled "Cancer Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cancer pain is a medical condition related to different oncology disorders in which there's a complex, unpleasant sensation that reflects both damage to the body and the body's reaction to the injury. It is often caused by the tumor pressing on nerves, bones, or other organs in the body. Depending on the causative factors and duration of the disease, this condition is categorized into acute and chronic cancer pain. In severe cases, the high-intensity pain can adversely affect the patient's sleep, social relations, mood, and activities of daily living. The primary indication of this illness includes aching, dull, or throbbing pain. Individuals suffering from the ailment may also experience a sensation of pressure, burning, or tingling, along with numerous psychological effects like increased feelings of helplessness, depression, anxiety, and despair. The diagnosis of cancer pain is made by reviewing a patient's medical history, underlying symptoms, and physical exam. The healthcare provider may predict the disease severity and guide its treatment using several assessment tools, including the Edmonton classification system for cancer pain (ECS-CP) and the cancer pain prognostic scale (CPPS).

The increasing prevalence of spreading or growing tumors, which can compress or damage tissues, resulting in infection and inflammation, is primarily driving the cancer pain market. In addition to this, the widespread adoption of non-opioid medications such

as dipyrrone, paracetamol, non-steroidal anti-inflammatory drugs, COX-2 inhibitors, etc., for treating mild to moderate symptoms is acting as another significant growth-inducing factor. These agents have a potentially lower risk of harming the patient and aid in alleviating pain by targeting specific pain-generating pathways. Moreover, the inflating demand for an intrathecal pump, which allows the administration of pain relievers directly to the affected nerves, thereby providing quicker relief compared to other conventional therapies, is also creating a positive outlook for the market. Apart from this, the emerging popularity of mind-body interventions, including biofeedback and relaxation techniques, to reduce the worsening of the condition in patients unresponsive to pharmacological drugs is further bolstering the market growth. Additionally, the increasing utilization of nerve blocks for treating acute and chronic pain since they provide targeted and immediate relief by directly blocking the transmission of pain signals from the damaged nerves is expected to drive the cancer pain market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the cancer pain market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cancer pain and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cancer pain market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cancer pain market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cancer pain market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cancer pain marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the cancer pain market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the cancer pain market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the cancer pain market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of cancer pain across the seven major markets?

What is the number of prevalent cases (2018-2034) of cancer pain by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of cancer pain by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with cancer pain across the seven major markets?

What is the size of the cancer pain patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of cancer pain?

What will be the growth rate of patients across the seven major markets?

Cancer Pain: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for cancer pain drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cancer pain market?

What are the key regulatory events related to the cancer pain market?

What is the structure of clinical trial landscape by status related to the cancer pain market?

What is the structure of clinical trial landscape by phase related to the cancer pain market?

What is the structure of clinical trial landscape by route of administration related to the cancer pain market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 CANCER PAIN - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 CANCER PAIN - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 CANCER PAIN - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 CANCER PAIN - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 CANCER PAIN - UNMET NEEDS

10 CANCER PAIN - KEY ENDPOINTS OF TREATMENT

11 CANCER PAIN - MARKETED PRODUCTS

- 11.1 List of Cancer Pain Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Lazanda (Fentanyl intranasal spray) - Kyowa Kirin International
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Abstral (Fentanyl sublingual) - Orexo
 - 11.1.2.1 Drug Overview

- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Quadramet (Samarium 153 lexidronam) - CIS bio internationa
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 SUBSYS (Fentanyl sublingual) - BTcP Pharma/Pharmbio Korea
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Sativex (Nabiximols) - GW Pharmaceuticals
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 CANCER PAIN - PIPELINE DRUGS

- 12.1 List of Cancer Pain Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 PPP001 - Tetra Bio-Pharma
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
 - 12.1.2 Resiniferatoxin - Sorrento Therapeutics
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy

- 12.1.2.5 Regulatory Status
- 12.1.3 NanaBis - Aphria/Medlab
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 Tetrodotoxin - WEX Pharmaceuticals
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. CANCER PAIN - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. CANCER PAIN – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 CANCER PAIN - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Cancer Pain - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Cancer Pain - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Cancer Pain - Market Size
 - 15.3.1.1 Market Size (2018-2023)

- 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Cancer Pain - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Cancer Pain - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Cancer Pain - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Cancer Pain - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Cancer Pain - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Cancer Pain - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Cancer Pain - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Cancer Pain - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Cancer Pain - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Cancer Pain - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Cancer Pain - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Cancer Pain - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Cancer Pain - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Cancer Pain - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Cancer Pain - Market Size

- 15.8.1.1 Market Size (2018-2023)
- 15.8.1.2 Market Forecast (2024-2034)
- 15.8.2 Cancer Pain - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Cancer Pain - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Cancer Pain - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Cancer Pain - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Cancer Pain - Access and Reimbursement Overview

16 CANCER PAIN - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 CANCER PAIN MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 CANCER PAIN MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Cancer Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/C95BB2D66C86EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C95BB2D66C86EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

